Cargando…

Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA

BACKGROUND: Immune-related adverse events (irAEs) are a serious side effect of immune checkpoint inhibitor (ICI) therapy for patients with advanced cancer. Currently, predisposing risk factors are undefined but understanding which patients are at increased risk for irAEs severe enough to require hos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalinich, Mark, Murphy, William, Wongvibulsin, Shannon, Pahalyants, Vartan, Yu, Kun-Hsing, Lu, Chenyue, Wang, Feicheng, Zubiri, Leyre, Naranbhai, Vivek, Gusev, Alexander, Kwatra, Shawn G, Reynolds, Kerry L, Semenov, Yevgeniy R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016099/ https://www.ncbi.nlm.nih.gov/pubmed/33789879 http://dx.doi.org/10.1136/jitc-2020-001935

Ejemplares similares

Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study
por: Tiu, Bruce C, et al.
Publicado: (2022)

Risk of COVID‐19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors
por: Klebanov, Nikolai, et al.
Publicado: (2021)

Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis
por: Durbin, Sienna M, et al.
Publicado: (2020)

Pericardial disease in patients treated with immune checkpoint inhibitors
por: Gong, Jingyi, et al.
Publicado: (2021)

Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
por: Zubiri, Leyre, et al.
Publicado: (2021)

Electrocardiographic features of immune checkpoint inhibitor associated myocarditis
por: Zlotoff, Daniel A, et al.
Publicado: (2021)

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
por: Rogiers, Aljosja, et al.
Publicado: (2021)

Immunosuppressive biologics did not increase the risk of COVID-19 or subsequent mortality: A retrospective matched cohort study from Massachusetts
por: Pahalyants, Vartan, et al.
Publicado: (2022)

C reactive protein impairs adaptive immunity in immune cells of patients with melanoma
por: Yoshida, Tatsuya, et al.
Publicado: (2020)

Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis
por: Badran, Yousef R, et al.
Publicado: (2023)

Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects
por: Delahousse, Julia, et al.
Publicado: (2020)

Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis
por: Chen, Xinru, et al.
Publicado: (2020)

Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients
por: Cuzzubbo, Stefania, et al.
Publicado: (2020)

Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition
por: Ghosh, Nilasha, et al.
Publicado: (2022)

Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
por: Beattie, Jason, et al.
Publicado: (2021)

Activin-A impairs CD8 T cell-mediated immunity and immune checkpoint therapy response in melanoma
por: Pinjusic, Katarina, et al.
Publicado: (2022)

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
por: Fa'ak, Faisal, et al.
Publicado: (2023)

Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study
por: Lee, Meghan D, et al.
Publicado: (2021)

Systemic inflammation shapes clinical outcomes in response to immune checkpoint blockade treatment: moving toward optimizing antitumor immunity
por: Zheng, Ming
Publicado: (2023)

Acute kidney injury in patients treated with immune checkpoint inhibitors
por: Gupta, Shruti, et al.
Publicado: (2021)

Immune checkpoint inhibitor-associated celiac disease
por: Badran, Yousef R, et al.
Publicado: (2020)

Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity
por: Abe, Shinya, et al.
Publicado: (2022)

Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression
por: Pierini, Stefano, et al.
Publicado: (2021)

Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma
por: Chen, Minjiang, et al.
Publicado: (2023)

IMMU-06. Landscape of adaptive immunity of childhood brain cancers
por: Raphael, Itay, et al.
Publicado: (2022)

Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI
por: Gupta, Shruti, et al.
Publicado: (2022)

Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma
por: Abou Alaiwi, Sarah, et al.
Publicado: (2020)

ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma
por: Sheng, Hailong, et al.
Publicado: (2020)

Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events
por: Siddiqui, Bilal A, et al.
Publicado: (2021)

Management of immune-related cutaneous adverse events with dupilumab
por: Kuo, Alyce Mei-Shiuan, et al.
Publicado: (2023)

Host response to immune checkpoint inhibitors contributes to tumor aggressiveness
por: Khononov, Irina, et al.
Publicado: (2021)

Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation
por: Wang, Minyu, et al.
Publicado: (2022)

28552 Risk of COVID-19 and subsequent mortality among patients receiving immunosuppressive biologic therapy: A retrospective matched cohort study
por: Pahalyants, Vartan, et al.
Publicado: (2021)

28630 Use of systemic immunosuppressive treatment is not related to COVID-19 positivity in a retrospective review of patients in Massachusetts
por: Murphy, William, et al.
Publicado: (2021)

Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
por: Kumar, Amrendra, et al.
Publicado: (2023)

IMMU-27. ANALYSIS OF IMMUNE SIGNATURES IN PEDIATRIC GLIOBLASTOMAS FOR PATIENT STRATIFICATION TO IMMUNOTHERAPY
por: Chandramohan, Vidyalakshmi, et al.
Publicado: (2020)

Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade
por: Luo, Yan, et al.
Publicado: (2023)

Efficacy and immune-related adverse event associations in avelumab-treated patients
por: Kelly, Karen, et al.
Publicado: (2020)

Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC
por: Massa, Chiara, et al.
Publicado: (2020)

WHSC1/NSD2 regulates immune infiltration in prostate cancer
por: Want, Muzamil Y, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u6b43r01lu98cioo21arfjugeu